114 results about "Interleukin 4" patented technology

This invention relates to a method for the biochemical treatment of persistent pain disorders by inhibiting the biochemical mediators of inflammation in a subject comprising administering to said subject any one of several combinations of components that are inhibitors of biochemical mediators of inflammation. Said process for biochemical treatment of persistent pain disorders is based on Sota Omoigui's Law, which states: ‘The origin of all pain is inflammation and the inflammatory response’. Sota Omoigui's Law of Pain unifies all pain syndromes as sharing a common origin of inflammation and the inflammatory response. The various biochemical mediators of inflammation are present in differing amounts in all pain syndromes and are responsible for the pain experience. Classification and treatment of pain syndromes should depend on the complex inflammatory profile. A variety of mediators are generated by tissue injury and inflammation. These include substances produced by damaged tissue, substances of vascular origin as well as substances released by nerve fibers themselves, sympathetic fibers and various immune cells. Biochemical mediators of inflammation that are targeted for inhibition include but are not limited to: prostaglandin, nitric oxide, tumor necrosis factor alpha, interleukin 1-alpha, interleukin 1-beta, interleukin-4, Interleukin-6 and interleukin-8, histamine and serotonin, substance P, Matrix Metallo-Proteinase, calcitonin gene-related peptide, vasoactive intestinal peptide as well as the potent inflammatory mediator peptide proteins neurokinin A, bradykinin, kallidin and T-kinin.

The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and/or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and/or antigenic components. APC are incubated in the presence of hsp-peptide complexes and/or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon- alpha , interferon- alpha , interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.

The invention provides an antibody capable of combining an interleukin 4(IL-4) acceptor (IL-4R). In addition, the invention provides a nucleic acid sequence for coding an antibody, a carrier containing the nucleic sequence and a host cell for converted or transfected by the carrier. Further, the invention provides a method for producing the antibody, a medical science application of the antibody and a kit containing the antibody.

This invention relates to an herbal composition for the treatment and remedy of bronchial respiratory difficulties, more particularly this invention describes the process of separation, physicochemical characterization and biological response evaluation of active components obtained from extracts of any plant parts including leaves, barks, roots and seeds of plants M. koenigii and P. betle in order to establish their role on the treatment and remedy of bronchial respiratory troubles.

The invention provides a preparation method of a large-scale culture dendritic cell vaccine. The preparation method comprises the following process steps of: performing in-vitro separation and purification on collected white blood cells in human peripheral blood by adopting a blood cell separation machine to obtain a large number of mononuclear cells, wherein the order of magnitude can be above 10<9>; using a human granulocyte-macrophage colony stimulating factor and interleukin 4 to induce the culture to obtain a large number of immature dendritic cells, wherein the order of magnitude can be above 10<8>; and loading a tumor specific antigen in the immature dendritic cells, and then obtaining the mature dendritic cell vaccine with an anti-tumor effect under the induction culture conditions of a tumor necrosis factor alpha and lipopolysaccharides. The invention further provides a multi-time and multi-treatment course clinical application of the dendritic cell vaccine obtained through the method.

This invention relates generally to a method for purifying Interleukin-4 or related variants from an Escherichia coli culture medium, where Interleukin-4 and its derivatives are expressed as insoluble protein aggregates, so-called inclusion bodies.

The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.

The invention relates to the technical field of cell culture, in particular to a culture medium, application thereof and a culture method. The culture medium comprises transferrin, recombinant human insulin, progesterone, fetal calf serum, stem cell growth factors, vitamin C, interleukin 2, interleukin 4, zinc sulfate and a DMEM/F12 culture medium. When the culture medium is used for culturing CD19-CAR-T cells, the cell proliferation multiple can be improved, the number of cell culture days is increased, and the CD19CAR and other surface markers can be kept expressed.

The invention discloses a protein chip capable of quickly providing early-stage depression pre-warning, and belongs to the field of biotechnology. The protein chip is a solid-phase microwell plate coated with the antibodies of TNF-alpha (tumor necrosis factor), IL-1 (interleukin-1), and IL-4 (interleukin-4). Reagents matched with the protein chip comprise the detecting antibodies of TNF-alpha, IL-1, and IL-4 labeled with biotin, and HRP (horse reddish peroxidase) labeled with avidin, and a substrate on which the HRP acts. An ELISA (enzyme linked immunosorbent assay) method is used for detecting the expression conditions of TNF-alpha, IL-1, and IL-4 in serum of an tested individual and normal people, if the expression quantity of TNF-alpha, IL-1, and IL-4 in the serum of the tested individual is obviously higher than that in the serum of the normal people, then the tested individual can be judged to have an early-stage depression propensity. The protein chip is used for providing early-stage depression pre-warning through protein levels. The protein chip has high sensitivity and specificity, is easy and quick to operate, good in stability and low in cost, and can be widely applied to the early-stage depression pre-warning.

The invention relates to a sutai pig common disease-resistance combined selection index selecting breeding method. The method comprises the steps that front-cavity venous blood of 35-day-old piglets is collected, concentration of interleukin 2(IL-2), concentration of interleukin 4(IL-4), concentration of interleukin 6(IL-6), concentration of interleukin 10(IL-10), concentration of interleukin 12(IL-12) and concentration of beta interferon (IF-N-beta) are measured after serum samples are obtained, test pig groups are grouped at the same time, then data of the six indexes are converted into standardization Z values, the standardization Z values are substituted into a built combined selection index formulation to calculate a combined selection index value of each pig group, and individuals having higher disease resistance generally are determined according to the values. The detection method is easy to operate, high in accuracy, and capable of achieving automatic direct detection, and will give great play to disease-resistance breeding practice of the pigs.

Provided are methods for the detection and diagnosis of Hypothyroidism. The methods are based on the discovery that altered levels of selected analytes in sample fluid, typically blood samples, of patients are supportive of a diagnosis of Hypothyroidism. At least twenty-four new biomarkers for hypothyroidism are thus disclosed (singly or in any combination), Thyroid Stimulating Hormone, Interleukin-12p40, Tumor Necrosis Factor Alpha, Tissue Factor, Interleukin-15, Insulin, Immunoglobulin E, Growth Stimulating Hormone, Calcitonin, Prostate-Specific Antigen, Interleukin-4, Granulocyte Macrophage Colony Stimulating Factor, Matrix Metalloproteinase 9, Lymphotactin, Fatty Acid Binding Protein, Alpha Fetoprotein, Alpha-2 Macroglobulin, Serum Glutamic Oxaloacetic Transaminase, Matrix Metalloproteinase 3, Cancer Antigen 125, Mumps Antibody, Double Stranded DNA Antibody, Proliferating Cell Nuclear Antigen Antibody, Smith Antibody, or Herpes Simplex Virus 1 Glycoprotein D Antibody. Altogether the concentrations of one or more of these analytes, as well as Thyroid Stimulating Hormone, or any combination thereof, provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from Hypothyroidism. Kits containing reagents to assist in the analysis of fluid samples are also described.

The invention provides a method for preparing dendritic cells. The method comprises the process of culturing to obtain dendritic cells which high-express costimulatory molecules such as 4-1BBL, CD80, CD83 and CD86 in the presence of a human granulocyte-macrophage colony stimulating factor, interleukin-4, phorbol myristate acetate and a tumor necrosis factor alpha. The invention also provides a kit, a kit product obtained by adopting the method provided by the invention and an application of the kit product in preparation of the dendritic cells. The kit product can be applied to fundamental research and clinical application of the dendritic cells.

The present invention relates generally to chemical agents useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory including allergic diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites. More particularly, the chemical agents contemplated by the present invention are selected from glycosaminoglycan (GAG) molecules derived from a larger GAG, GAG-like molecules which resemble GAGs in some of their characteristics but may be derived from a larger non-GAG polysaccharide and molecules having a GAG-like composite structure as well as agents which bind to the same sites as GAGs, GAG-like molecules or GAG-like composite molecules. The present invention also provides assays to identify GAG and GAG-like therapeutic agents including GAG-like composite structures as well as analogs, homologs and orthologs thereof.

An anti-infectious immunopotentiator for animals is prepared through cloning the interleukin-4 gene of Tibetan pig, configuring its eukaryon expression plasmid VTPIL-4, preparing chitosan nanoparticles from deacetyl chitosan, and using said chitosan nanoparticles for molecular packaging of plasmid VTPIL-4. It can be used for immunizing experimental animal by intramuscular injection.

The invention discloses an interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals. The interleukin-4 therapeutic vaccine is a protein vaccine or coupling protein vaccine of any form prepared by taking the natural or artificially synthesized complete protein or protein fragment of interleukin-4 as an antigen; or the interleukin-4 therapeutic vaccine is a gene vaccine or fusion gene vaccine of any form prepared by taking the complete gene or gene fragment of interleukin-4 as the antigen gene or the major antigen gene. The IL (interleukin)-4 vaccine is used for performing active immunotherapy on a host, generally, the effective time lasts for about 2-3 months by immunization for the first time, the effective therapeutic time lasts for about half a year by secondary immunization, and recovery can be achieved by 1-3 times of immunotherapy. Compared with direct application of anti-IL-4 antibody for treatment, the invention has the characteristics of few times of application, low dose and the like, thereby greatly reducing the therapeutic cost, and also greatly reducing the possibility of generating allergic reaction.

This invention provides the coding sequence of recombination human interleukin-4, and method for producing said interleukin-4, and also the expression vactor and host cells used for said method. In this invention, pET system for expression of IL-4 is firstly used for obtaining high leven expression strain; and by controlling fermentation condition, the higher level of protein expression is obtained. Based on this and after large scale of research of purification of recombination human interleukin-4 of inclusion body expression, we obtain the method of purification of IL-4. By using this invention method, recombination human interleukin-4 protein can be obtained with high yield and high purity, to meet the clinical needs. This invention method is of high efficiency, simple and low cost.

The invention discloses Artocarpus lingnanensis lectin capable of inducing dentritic cells (DC) to mature and proliferate in vitro, a special culture medium for inducing DC to mature and proliferate, and a preparation method for the DC. The Artocarpus lingnanensis lectin is prepared from red cassia tree seeds through separation and purification by the conventional separation method. According to the special culture medium, inducing factors and the Artocarpus lingnanensis lectin are added into a DC culture medium. The preparation method comprises the following steps: adding precursor cells of the DC and the inducing factors into the DC culture medium, and adding the Artocarpus lingnanensis lectin when the cells are cultured in the sixth day; and continuously culturing to obtain mature DC, wherein the precursor cells are peripheral blood mononuclear cells; and the inducing factors are granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). A stable culture technical system for inducing the DC to mature and proliferate is established, and is easy to operate, convenient and practical; the required cell factors are a few, and the cost is low; and the dentritic cells (DC) have high maturity and strong functions. The Artocarpus lingnanensis lectin provides a novel effective way for further developing vaccine enhancers.

The invention discloses a method for screening probiotics. The method comprises the following steps of: (1) carrying out a primary culture on spleen tissues of a pig or a domestic animal; (2) attacking toxicity of the tissues through colon bacillus K88, and testing variations of levels of an interleukin 8 and an interleukin 4; (3) respectively processing the tissues through candidate probiotic strains, and testing variations of levels of two interleukins; (4) comparing the variations to select probiotic strains which are similar in variation degrees of the two interleukins but opposite in effect due to treatment of the colon bacillus K88; and (5) through the colon bacillus K88 animal toxicity attacking test, observing protecting effects of primarily selected probiotic strains, and finally determining an efficient probiotic strain. The method for screening the probiotic disclosed by the invention has the remarkable advantages that: the method combining in vitro immunology experiment and in vivo toxicity attacking experiment is high in accuracy, strong in pertinency and time-saving; and the screened probiotics can effectively replace antibiotic, and greatly reduce diseases caused by colon bacillus so as to promote the health of the animal.

The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation.

A method for renaturation of proteins comprising adding to a solution of denatured, chemically modified or reduced proteins a refolding buffer containing a primary, secondary or tertiary amine. Said method has been applied, for example, to interleukin-4 and bovine pancreatic trypsin inhibitor (BPTI), wich were previously (i) solubilized in the presence of guanidinium hydrochloride as chaotronic agent, and (ii) subjected to sulfitolysis.

Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.

The invention provides a method for performing quantitative determination to immunity-relating cytokine in peripheral blood, the method can be applied for specifically detect the cytokine gene expression (IL-4) from 2ml of peripheral blood, and no any stimulation is needed before detection. The method can detect the cytokine gene expression under physiologic status, thus can be used for determining early stage fatigue, preventing decrease of body immunity function caused by exercises of excess sport load. The invention also provides a corresponding detection kit.

The invention belongs to the field of biological cells and relates to a method for polarizing and amplifying CD4+T cells and application. The method includes that human-source or rat-source CD4+ undifferentiated T cells are adopted, and a series of cell factors like T cell activation and conversion growth factor beta, interleukin-4, interlenkin-21 and gamma-interferon neutralizing antibody are adopted for co-stimulation. By the method, destructiveness and self-differentiation multiplication ability for cancer cells are maintained while T cells polarized by the method are multiplied massively such as by 500-1000 times within 14 days. The T cells are different from anticancer subgroup like Th1, Th17 and Th9 reported before in character and exceed the same in cancer killing efficacy to some extent. CD4+T cell subgroup polarized by the method has strong treatment effect on various cancers like solid and blood tumor expressing specific antigen.